Mylan N.V. (MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion for the marketing authorization application of Hulio, the companies' biosimilar to Humira, or adalimumab, for all indications.
from RTT - Biotech https://ift.tt/2va3dTf
via IFTTT
No comments:
Post a Comment